Results 1 to 10 of about 11,732 (171)

NALIRIFOX versus FOLFIRINOX: reconstructed individual patient data meta-analysis of efficacy and safety in first-line treatment of unresectable or metastatic pancreatic ductal adenocarcinoma [PDF]

Frontiers in Oncology
BackgroundPancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal human malignancies, with a 5-year overall survival rate below 10%.
Abdullah Esmail, Abdullah Esmail, Jian Guan, Jian Guan, Zaid Alabed, Yazan Hamdaneh, Ebtesam Al-Najjar, Saifudeen Abdelrahim, Nour Mustafa, Bayan Khasawneh, Maen Abdelrahim, Maen Abdelrahim, Maen Abdelrahim   +12 more
doaj   +2 more sources

Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis

Therapeutic Advances in Medical Oncology, 2023
Background: FOLFIRINOX, used in metastatic pancreatic cancer (MPC), is highly efficacious but also toxic. Various dose modifications for FOLFIRINOX have been introduced to reduce toxicity.
Jong-Chan Lee
exaly   +2 more sources

Efficacy of immune checkpoint inhibitors combined with different chemotherapy in recurrent pancreatic cancer: a retrospective study [PDF]

Frontiers in Immunology
ObjectiveRecurrence affects 65%-75% of pancreatic cancer (PC) patient post-resection. Established salvage strategies for recurrent PC are lacking, and systemic chemotherapy offers limited survival benefits.
Qiang Tao, Qiang Tao, Lingmin Jiang, Lingmin Jiang, Lingmin Jiang, Ruiqi Wang, Ruiqi Wang, Xin Huang, Xin Huang, Pu Xi, Jun Wang, Jun Wang, Shengping Li, Shengping Li, Chaobin He, Chaobin He   +15 more
doaj   +2 more sources

Optimized chemotherapy sequence for metastatic pancreatic ductal adenocarcinoma patients: FOLFIRINOX followed by Gemcitabine plus nab-paclitaxel [PDF]

BMC Cancer
Background Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, usually diagnosed at late stages, at which point the best option is palliative chemotherapy.
Rocío del Campo-Pedrosa, Alfonso Martín-Carnicero, Ana González-Marcos, Alfredo Martínez   +3 more
doaj   +2 more sources

Second-line Modified GTX versus Gemcitabine-Nab-Paclitaxel (GmAb) Following First-Line FOLFIRINOX in Advanced Pancreatic Cancer: A Retrospective Analysis at the American University of Beirut Medical Center (AUBMC) [PDF]

Middle East Journal of Cancer, 2023
Background: Pancreatic cancer is characterized by its generally poor prognosis and ranks seventh worldwide in cancer-related mortality. We previously conducted a prospective study on the use of modified GTX regimen (a combination of gemcitabine ...
Sally Temraz, Firas Kreidieh, Farah Nassar, Maria Mezher, Deborah Mukherji, Ali Shamseddine   +5 more
doaj   +1 more source

Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX

Gut and Liver, 2021
Background/Aims: Although many studies have reported the promising effect of neoadjuvant treatment for borderline resectable pancreatic cancer (BRPC) to increase resectability, only a few studies have recommended the use of first-line chemotherapeutic ...
Yoo Jin Choi, Yoonhyeong Byun, Jae Seung Kang, Hyeong Seok Kim, Youngmin Han, Hongbeom Kim, Wooil Kwon, Do-Youn Oh, Woo Hyun Paik, Sang Hyub Lee, Ji Kon Ryu, Yong-Tae Kim, Kyungbun Lee, Haeryoung Kim, Eui Kyu Chie, Jin-Young Jang   +15 more
doaj   +1 more source

Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line

Case Reports in Oncology, 2020
Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at an advanced or metastatic stage, when curative surgery is not recommended. Therefore, the prognosis is poor for this dismal disease, with only 1–2% of the patients reaching the 5-year ...
Dilara Akhoundova Sanoyan, Cäcilia S. Reiner, Panagiota Papageorgiou, Alexander R. Siebenhüner   +3 more
doaj   +1 more source

Circulating mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX

Therapeutic Advances in Medical Oncology, 2021
Background: Biomarkers predicting treatment response may be used to stratify pancreatic ductal adenocarcinoma (PDAC) patients for therapy. The aim of this study was to identify circulating tumor DNA (ctDNA) mutations that associate with tumor progression
Fleur van der Sijde, Zakia Azmani, Marc G. Besselink, Bert A. Bonsing, Jan Willem B. de Groot, Bas Groot Koerkamp, Brigitte C. M. Haberkorn, Marjolein Y. V. Homs, Wilfred F. J. van IJcken, Quisette P. Janssen, Martijn P. Lolkema, Saskia A. C. Luelmo, Leonie J. M. Mekenkamp, Dana A. M. Mustafa, Ron H. N. van Schaik, Johanna W. Wilmink, Eveline E. Vietsch, Casper H. J. van Eijck   +17 more
doaj   +1 more source

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis

World Journal of Surgical Oncology, 2021
Background The prognosis of pancreatic cancer (PC) is extremely poor, and most patients with metastatic PC still receive palliative care. Here, we report the efficacy and safety of FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, 5-fluorouracil) in the ...
Beilei Zhang, Fengyan Zhou, Jiaze Hong, Derry Minyao Ng, Tong Yang, Xinyu Zhou, Jieyin Jin, Feifei Zhou, Ping Chen, Yunbao Xu   +9 more
doaj   +1 more source

Total neoadjuvant chemotherapy according to the FOLFIRINOX regimen for locally advanced adenocarcinoma of the stomach and cardioesophageal junction: interim results

Исследования и практика в медицине, 2023
Purpose. To study the efficacy and safety of total neoadjuvant chemotherapy (NACT) with the FOLFIRINOX regimen for locally advanced gastric (GC) and cardioesophageal junction (CEJ) cancer.Patients and methods.
M. V. Sedova, M. A. Batov, A. A. Kolomeytseva, V. M. Khomyakov, N. N. Volchenko, A. A. Fedenko   +5 more
doaj   +1 more source